NEW YORK, Feb 18 (Reuters) - Johnson & Johnson said it has recalled two lots of Simponi injection devices -- one in the United States and one in Europe -- after discovering they may deliver less than ...

Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...

The Simponi recall stemmed from a manufacturing problem in Switzerland. As Dow Jones reports, many of the affected lots were set aside before hitting the market, but some 395 of the prefilled ...

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

For the third time this week, we're reporting on a Johnson & Johnson recall. (See hereand herefor the other two.) This time the recall seems to involve only a few hundred units. As Dow Jones Newswires ...

April 27, 2009 — The US Food and Drug Administration (FDA) has approved golimumab (Simponi, Centocor Ortho Biotech Inc) for monthly subcutaneous injection in the treatment of adults with ...

NEW YORK, Oct 17 (Reuters) - Johnson & Johnson's new rheumatoid arthritis drug, Simponi, when used in combination with the common treatment methotrexate was significantly more effective at inhibiting ...

The Simponi recall marks the fourth medical device recall from J&J in recent weeks. Previously, the company recalled its schizophrenia treatment Invega Sustenna for cracked syringes, hernia device ...

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis. Simponi works by blocking tumor necrosis ...

If needed, Simponi Aria may be stored at room temperature up to 77⁰F (25⁰C) for a maximum single period of 30 days in the original carton to protect from light. Once Simponi Aria has been stored at ...

HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing ...

The US Food and Drug Administration (FDA) today approved a new indication for the tumor necrosis factor (TNF)-alpha inhibitor golimumab (Simponi, Janssen Biotech): treatment of adults with moderate to ...